17-31156122-A-G
Variant summary
Our verdict is Likely benign. The variant received -1 ACMG points: 2P and 3B. PM2BP4_ModerateBS2_Supporting
The NM_001042492.3(NF1):c.200A>G(p.Asn67Ser) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000342 in 1,461,410 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. N67D) has been classified as Likely benign.
Frequency
Consequence
NM_001042492.3 missense
Scores
Clinical Significance
Conservation
Publications
- neurofibromatosis type 1Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, PanelApp Australia, G2P, Genomics England PanelApp
- neurofibromatosis-Noonan syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Genomics England PanelApp, PanelApp Australia
- Moyamoya diseaseInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- hereditary pheochromocytoma-paragangliomaInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- familial ovarian cancerInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -1 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt | 
|---|---|---|---|---|---|---|---|---|
| NF1 | NM_001042492.3 | c.200A>G | p.Asn67Ser | missense_variant | Exon 2 of 58 | ENST00000358273.9 | NP_001035957.1 | |
| NF1 | NM_000267.4 | c.200A>G | p.Asn67Ser | missense_variant | Exon 2 of 57 | NP_000258.1 | ||
| NF1 | NM_001128147.3 | c.200A>G | p.Asn67Ser | missense_variant | Exon 2 of 15 | NP_001121619.1 | 
Ensembl
Frequencies
GnomAD3 genomes  
GnomAD2 exomes  AF:  0.00000796  AC: 2AN: 251220 AF XY:  0.00000736   show subpopulations 
GnomAD4 exome  AF:  0.00000342  AC: 5AN: 1461410Hom.:  0  Cov.: 32 AF XY:  0.00000275  AC XY: 2AN XY: 727032 show subpopulations 
Age Distribution
GnomAD4 genome  
ClinVar
Submissions by phenotype
Neurofibromatosis, type 1    Uncertain:3 
- -
This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 67 of the NF1 protein (p.Asn67Ser). This variant is present in population databases (rs375038808, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with NF1-related conditions. ClinVar contains an entry for this variant (Variation ID: 232106). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt NF1 protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
- -
Juvenile myelomonocytic leukemia    Uncertain:1 
- -
not provided    Uncertain:1 
In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge -
Hereditary cancer-predisposing syndrome;CN230736:Cardiovascular phenotype    Uncertain:1 
The c.200A>G (p.N67S) alteration is located in exon 2 (coding exon 2) of the NF1 gene. This alteration results from a A to G substitution at nucleotide position 200, causing the asparagine (N) at amino acid position 67 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
Hereditary cancer-predisposing syndrome    Uncertain:1 
The p.N67S variant (also known as c.200A>G), located in coding exon 2 of the NF1 gene, results from an A to G substitution at nucleotide position 200. The asparagine at codon 67 is replaced by serine, an amino acid with highly similar properties. This variant was previously reported in the SNPDatabase as rs375038808. Based on data from the NHLBI Exome Sequencing Project (ESP), the G allele has an overall frequency of approximately 0.02% (2/13006) total alleles studied, having been observed in0.02% (2/8600) European American alleles.This variant was not reported in the 1000 Genomes Project population-based cohort. To date, this alteration has been detected with an allele frequency of approximately 0.002% (greater than 55000alleles tested) in our clinical cohort.This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis.Since supporting evidence is limited at this time, the clinical significance of p.N67Sremains unclear. -
Computational scores
Source: 
Splicing
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at